GRI Bio to Present at the 2024 European Respiratory Congress
GRI Bio (NASDAQ: GRI), a biotech company developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the 2024 European Respiratory Congress (ERS) in Vienna, Austria. The company's abstract has been accepted for a poster presentation on September 9, 2024.
The presentation, titled 'Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis', will be delivered by Emily Calamita from Dr. Adam Byrne's laboratory at Imperial College London. This research aligns with GRI Bio's focus on NKT cell modulators and their potential applications in treating respiratory conditions.
The poster session, scheduled from 12:30 - 2:00 PM CEST, falls under the category of 'Novel Insights in the Pathogenesis of Pulmonary Fibrosis', highlighting the company's contributions to advancing understanding in this field.
GRI Bio (NASDAQ: GRI), una compagnia biotecnologica che sviluppa modulatori delle cellule T killer naturali (NKT) per malattie infiammatorie, fibrotiche e autoimmuni, ha annunciato la sua partecipazione al 2024 European Respiratory Congress (ERS) che si terrà a Vienna, Austria. L'abstract dell'azienda è stato accettato per una presentazione poster il 9 settembre 2024.
La presentazione, intitolata 'Le cellule T killer naturali invarianti di Tipo 1 promuovono la fibrosi polmonare', sarà eseguita da Emily Calamita del laboratorio del Dott. Adam Byrne all'Imperial College di Londra. Questa ricerca è in linea con l'attenzione di GRI Bio sui modulatori delle cellule NKT e le loro potenziali applicazioni nel trattamento delle condizioni respiratorie.
La sessione dei poster, programmata dalle 12:30 alle 14:00 CEST, rientra nella categoria 'Nuove intuizioni nella patogenesi della fibrosi polmonare', evidenziando i contributi dell'azienda per avanzare nella comprensione di questo campo.
GRI Bio (NASDAQ: GRI), una compañía biotecnológica que desarrolla moduladores de células T asesinas naturales (NKT) para enfermedades inflamatorias, fibróticas y autoinmunes, ha anunciado su participación en el 2024 European Respiratory Congress (ERS) en Viena, Austria. El resumen de la compañía ha sido aceptado para una presentación en póster el 9 de septiembre de 2024.
La presentación, titulada 'Las células T asesinas naturales invariantes de Tipo 1 impulsan la fibrosis pulmonar', será realizada por Emily Calamita del laboratorio del Dr. Adam Byrne en el Imperial College de Londres. Esta investigación está alineada con el enfoque de GRI Bio en los moduladores de células NKT y sus posibles aplicaciones en el tratamiento de condiciones respiratorias.
La sesión de pósters, programada de 12:30 a 14:00 CEST, se inscribe en la categoría de 'Nuevas Perspectivas en la Patogénesis de la Fibrosis Pulmonar', destacando los aportes de la compañía para avanzar en la comprensión de este campo.
GRI Bio (NASDAQ: GRI)는 염증성, 섬유화 및 자가면역 질환을 위한 자연 살해 T 세포(NKT) 조절제를 개발하는 생명공학 회사로, 오스트리아 비엔나에서 열리는 2024 유럽 호흡기 학회 (ERS)에 참가한다고 발표했습니다. 회사의 초록은 2024년 9월 9일 포스터 발표를 위해 수락되었습니다.
이 발표는 런던 임페리얼 칼리지의 아담 번 박사 실험실에서 에밀리 칼라미타가 진행하며, 제목은 '1형 불변 자연 살해 T세포가 폐 섬유증을 유발한다'입니다. 이 연구는 GRI Bio가 NKT 세포 조절제에 집중하고 있으며 호흡기 질환 치료에 있어 그 잠재적 응용을 지향하고 있습니다.
포스터 세션은 CEST 기준으로 오후 12시 30분에서 2시 사이에 진행되며, '폐 섬유증의 병리학적 기전에 대한 새로운 통찰'이라는 범주에 포함되어 있어 회사의 기여가 이 분야에 대한 이해를 높이는 데 어떤 역할을 하는지를 강조합니다.
GRI Bio (NASDAQ: GRI), une société biopharmaceutique développant des modulateurs de cellules T tueuses naturelles (NKT) pour les maladies inflammatoires, fibrotiques et auto-immunes, a annoncé sa participation au 2024 European Respiratory Congress (ERS) à Vienne, Autriche. Le résumé de la société a été accepté pour une présentation par affiche le 9 septembre 2024.
La présentation, intitulée 'Les cellules T tueuses naturelles invariantes de type 1 favorisent la fibrose pulmonaire', sera réalisée par Emily Calamita du laboratoire du Dr. Adam Byrne à l'Imperial College de Londres. Cette recherche s'aligne avec l'objectif de GRI Bio concernant les modulateurs de cellules NKT et leurs applications potentielles dans le traitement des affections respiratoires.
La session des posters, prévue de 12h30 à 14h00 CEST, est classée dans la catégorie 'Nouvelles perspectives sur la pathogenèse de la fibrose pulmonaire', mettant en avant les contributions de la société pour faire progresser la compréhension de ce domaine.
GRI Bio (NASDAQ: GRI), ein biotechnologisches Unternehmen, das Modulatoren der natürlichen Killer-T-Zellen (NKT) für entzündliche, fibrotische und autoimmunen Erkrankungen entwickelt, hat seine Teilnahme am 2024 European Respiratory Congress (ERS) in Wien, Österreich, angekündigt. Das Abstract des Unternehmens wurde für eine Posterpräsentation am 9. September 2024 angenommen.
Die Präsentation mit dem Titel 'Typ 1 Invariante natürliche Killer-T-Zellen fördern die Lungenfibrose' wird von Emily Calamita aus dem Labor von Dr. Adam Byrne am Imperial College London gehalten. Diese Forschung steht im Einklang mit dem Fokus von GRI Bio auf NKT-Zellmodulatoren und deren potenziellen Anwendungen zur Behandlung von Atemwegserkrankungen.
Die Postersitzung, die von 12:30 bis 14:00 Uhr CEST stattfindet, fällt in die Kategorie 'Neue Einblicke in die Pathogenese der Lungenfibrose' und hebt die Beiträge des Unternehmens zur Förderung des Verständnisses in diesem Bereich hervor.
- None.
- None.
LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for a poster presentation at the 2024 European Respiratory Congress (ERS) being held September 7-11, 2024 in Vienna, Austria.
Details of the poster presentation are as follows:
Title: Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis
Presenter: Emily Calamita of Dr. Adam Byrne’s laboratory, Imperial College London
Poster Number: PA3381
Session: Novel Insights in the Pathogenesis of Pulmonary Fibrosis
Date and Time: September 9, 2024, from 12:30 - 2:00 PM CEST
For more information about the event, please visit the conference website here.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
FAQ
When and where is GRI Bio presenting at the 2024 European Respiratory Congress?
What is the title of GRI Bio's poster presentation at ERS 2024?
Who is presenting GRI Bio's research at the 2024 European Respiratory Congress?
What is the focus of GRI Bio's research presented at ERS 2024?
What types of diseases is GRI Bio targeting with its NKT cell modulator pipeline?
